Home
Technology Platforms
Harbour Mice
®
Single Cell Technology Platform
HBICE
®
Fully Human Generative AI HCAb Model
Therapeutics
Inflammatory & Immunology Diseases
Oncology/Immuno-Oncology
Weight Management
Publications
Harbour Medical
Overview
Clinical Development & Medical Services
Scientific Committee
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Partnership
Technology Service
Technology License
Asset License
Co-development
Strategic Collaboration
Cooperation Contact
About Us
Company Overview
Corporate Strategy
Management Team
Scientific Advisory Board
Our History
Our Locations
Newsroom
Investor Relations
Corporate Governance
Stock Information
Disclosure
Financials
Presentations and Events
Analyst Coverage
Notices-Replacement of Lost Share Certificates
Subscribe to Updates
Careers
中国 — 简体中文
Global — English
Home
Technology Platforms
BACK
Technology Platforms
Harbour Mice
®
Single Cell Technology Platform
HBICE
®
Fully Human Generative AI HCAb Model
Therapeutics
BACK
Therapeutics
Inflammatory & Immunology Diseases
Oncology/Immuno-Oncology
Weight Management
Publications
Harbour Medical
BACK
Harbour Medical
Overview
Clinical Development & Medical Services
Scientific Committee
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Partnership
BACK
Partnership
Technology Service
Technology License
Asset License
Co-development
Strategic Collaboration
Cooperation Contact
About Us
BACK
About Us
Company Overview
Corporate Strategy
Management Team
Scientific Advisory Board
Our History
Our Locations
Newsroom
Investor Relations
BACK
Investor Relations
Corporate Governance
Stock Information
Disclosure
Financials
Presentations and Events
Analyst Coverage
Notices-Replacement of Lost Share Certificates
Subscribe to Updates
Careers
Newsroom
Strive to Deliver Breakthroughs
Press Release
particular year
Please select
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
03
Please select
01
02
03
04
05
06
07
08
09
10
11
12
2026-03-30
Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
2026-03-23
Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
2026-03-19
Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation
2026-03-09
Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis
2025-03-31
Harbour BioMed Reports Full Year 2024 Financial Results
2025-03-21
Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies
2025-03-12
Harbour BioMed Launches 脡lanc茅 Therapeutics to Advance Next-Generation Obesity Therapies
2025-03-11
Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal
2025-03-11
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer
2024-03-28
Harbour BioMed Reports Full Year 2023 Financial Results
1
2
Jump